已發(fā)表的部分文獻: 標題:Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.作者:Katz TA, Vasilatos SN, Harrington E, Oesterreich S, Davidson NE, Huang Y;雜志名稱:Breast Cancer Res Treat 標題:Oct4 mediated inhibition of Lsd1 activity promotes the active and primed state of pluripotency enhancers作者:AlAbdi L. et al.;雜志名稱:bioRxiv 標題:LSD1 inhibition yields functional insulin-producing cells from human embryonic stem cells.作者:He F, Li N, Huang HB, Wang JB, Yang XF, Wang HD, Huang W, Li FR;雜志名稱:Stem Cell Res Ther 標題:Human epidermal growth factor receptor 2 inhibits activating transcription factor 7 to promote breast cancer cell migration by activating histone lysine demethylase 1.作者:Lin J, Mao H, Ji Z, Lin W, Wang T;雜志名稱:J Cancer Res Ther 標題:Modulation of the activity of histone lysine methyltransferases and demethylases by curcumin analog in leukaemia cells.作者:Sawesi S, Malkaram SA, Abd Elmageed ZY, Fandy TE;雜志名稱:J Cell Mol Med Epigentek 公司是全球領先的表觀遺傳學相關(guān)研究的技術(shù)創(chuàng)新者和產(chǎn)品開發(fā)供應商。開發(fā)了超過700多個專利產(chǎn)品,為表觀遺傳學方面的研究和新藥研發(fā)提供全面系統(tǒng)的解決方案,涵蓋樣品制備、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、組蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等領域,提供小分子抑制劑、蛋白質(zhì)、抗體、以及分析試劑盒產(chǎn)品。